Section Arrow
MNKD.NASDAQ
- MannKind Corp
  suspend
Quotes are at least 15-min delayed:2026/04/28 13:36 EDT
Regular Hours
Last
 2.765
+0.135 (+5.13%)
Day High 
2.8099 
Prev. Close
2.63 
1-M High
2.98 
Volume 
3.44M 
Bid
2.76
Ask
2.77
Day Low
2.6501 
Open
2.67 
1-M Low
2.29 
Market Cap 
812.13M 
Currency 美元 
P/E 131.5 
%Yield -- 
10-SMA 2.75 
20-SMA 2.64 
50-SMA 3.09 
52-W High 6.51 
52-W Low 2.23 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.02/0.13
Enterprise Value
1.14B
Balance Sheet
Book Value Per Share
-0.17
Cash Flow
Cash Flow Yield
0.02
Income Statement
Total Revenue
348.97M
Operating Revenue Per Share
0.57
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ERASErasca10.11-9.04-47.21%-- 
CLDICalidi Biotherapeutics0.2202-0.0173-7.28%0.66PE
CMPXCompass Therapeutics1.855+0.065+3.63%-- 
SNGXSoligenix Inc.0.422-0.993-70.18%-- 
BBIOBridgeBio Pharma70.66-3.86-5.18%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Companyis currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.